What do primary care providers need to know about PCPs in Diabetes, atrial Fibrillation, Mild Cognitive Impairment? Join expert faculty as they review important questions they get asked about these topics!

What do primary care providers (physicians, nurse practitioners, and physician assistants) need to know about caring for patients with Alzheimer’s disease (AD)? Primary care providers (PCPs) are well positioned to spot the earliest signs of cognitive decline — and patients are more likely to discuss sensitive topics, such as cognitive concerns, with a provider they know and trust. This engaging activity will provide you with the latest information regarding the role of PCPs in early diagnosis of AD, approaches to address racial and ethnic barriers to dementia-related care, and strategies to encourage collaboration among PCPs and AD specialists. Patient-specific management considerations, including the role of recently approved and emerging disease-modifying therapies, will also be addressed. Following completion of this 60-minute educational activity, you will be better equipped to optimize care for your patients with AD.

In this AdaptED learning module, learners will engage with the adaptive learning algorithm to explore the assessment and diagnosis of Alzheimer disease (AD). The activity will provide practical guidance for primary care providers on the clinical diagnosis of AD, including cognitive testing. It will also discuss neuroimaging and fluid markers to aid in diagnosis and monitoring of AD, including ongoing research in serum biomarkers that may soon expedite disease recognition. The AdaptED module will provide learners with evidence-based education in a convenient format that facilitates quick application of the material.

Despite the growing prevalence and devastating effects of Alzheimer disease (AD), mild cognitive impairment (MCI) often goes unrecognized in the primary care setting. This brief podcast highlights the need for primary care providers to identify individuals with MCI as early as possible so they can be assessed and, if diagnosed with AD, treated promptly. Expert faculty will explore the manifold benefits of early evaluation, which can include identifying reversible causes of MCI, taking advantage of new effective treatments, and reducing patients’ risk of premature mortality. You’ll walk away from this podcast with strategies to help you earlier identify these patients and, ultimately, maintain their cognitive abilities and quality of life for a longer period.

This short podcast will focus on new and emerging monoclonal antibody therapies targeting β-amyloid, with a focus on the importance of early recognition and diagnosis of Alzheimer disease to allow prompt treatment for patients in the early stages of the disease who may derive the most benefit from these agents.

Alzheimer disease (AD) is a growing concern as the population ages. Primary care clinicians are often the first to screen for and identify signs of cognitive impairment which may be due to AD. Join neurologist Gad Marshall, MD in this two-part podcast series, as he answers important questions and provides helpful tips for assessing cognitive impairment in primary care and provides insight into the current and emerging role of neuroimaging and biomarkers in the diagnosis of AD. The topics covered in this podcast are based on challenges and misconceptions identified from the CME/CE curriculum The Future of Alzheimer Disease: Early Recognition and Emerging Therapy.

Alzheimer disease (AD) treatment is evolving. With this rapid expansion in potential therapies, there remain challenges and misconceptions. Join neurologist Gad Marshall, MD in this two-part podcast series, as he answers important questions about new and emerging disease-modifying therapies and explores ways in which these treatments may be considered in the future for patients. The topics covered in this podcast are based on challenges and misconceptions identified from the CME/CE curriculum The Future of Alzheimer Disease: Early Recognition and Emerging Therapy.

As people get older, it is challenging to determine what screening tests make a difference in their lives and are truly necessary. Providers are inundated with sweeping quality improvement strategies that often do not reflect the needs of older adult patients. Learn from an expert geriatrician, through a red-yellow-green light approach, on which tests are good, questionable, and bad.

Polypharmacy is a burden on patients with dementia. Adverse drug reactions, side effects, the cost, and inappropriate medications that may lead to falls and morbidity/mortality may be conferring more harm than benefit. Unfortunately, 44% of men and 57% of women >65 years take five or more nonprescription and/or prescription medications per day. Join us as we discuss methods for deprescribing polypharmacy in this patient population.

Older adults who suffer from loneliness may be at risk of overusing medications prescribed for pain, insomnia, depression, or anxiety. Replacing these medications with social interventions may improve outcomes and help patients avoid adverse consequences. Join us as we discuss the importance of reviewing medications and assessing for loneliness in older adults to prevent adverse events and outcomes.